APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
-0.10% today
Updated 2026-04-29
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.4M
Apellis Pharmaceuticals Inc (APLS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $250.65M | $66.56M | $75.42M | $396.59M | $781.37M | $1.00B |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | -73.4% | +13.3% | +425.8% | +97.0% | +28.5% |
| Cost of revenue | — | $0.00 | $0.00 | $0.00 | $50.77M | $127.92M | $595449.00 | $25.05M | $5.20M | $5.64M | $58.51M | $117.72M | $102.24M |
| Gross profit | — | $0.00 | $0.00 | $0.00 | $-50.77M | $-127.92M | $-595449.00 | $225.60M | $61.36M | $69.79M | $338.08M | $663.64M | $901.55M |
| Gross margin | — | — | — | — | — | — | — | 90.0% | 92.2% | 92.5% | 85.2% | 84.9% | 89.8% |
| R&D | $2.32M | $8.38M | $13.73M | $22.98M | $40.30M | $105.29M | $220.97M | $299.92M | $420.87M | $387.24M | $354.39M | $327.57M | $295.85M |
| SG&A | $1.71M | $2.91M | $6.36M | $4.30M | $10.46M | $22.64M | $67.05M | $139.40M | $176.77M | $277.16M | $500.81M | $417.75M | $550.26M |
| Operating income | $-4.03M | $-11.29M | $-46.57M | $-27.28M | $-50.77M | $-127.92M | $-288.02M | $-213.73M | $-536.28M | $-594.61M | $-517.12M | $-164.98M | $55.43M |
| Operating margin | — | — | — | — | — | — | — | -85.3% | -805.7% | -788.4% | -130.4% | -21.1% | 5.5% |
| EBITDA | $-4.02M | $-11.29M | $6.40M | $-27.28M | $-50.90M | $-125.07M | $-298.83M | $-312.23M | $-731.27M | $-617.39M | $-495.21M | $-154.53M | $70.00M |
| EBITDA margin | — | — | — | — | — | — | — | -124.6% | -1098.6% | -818.6% | -124.9% | -19.8% | 7.0% |
| EBIT | $-4.03M | $-11.29M | $-46.57M | $-27.28M | $-50.91M | $-128.01M | $-299.42M | $-313.09M | $-732.76M | $-618.88M | $-496.92M | $-156.32M | $68.44M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $96915.00 | $2.51M | $5.29M | $29.94M | $13.24M | $32.63M | $29.58M | $40.39M | $44.33M |
| Income tax | — | $-443000.00 | $-26.54M | $-27.28M | $250607.00 | $-533000.00 | $5.11M | $1.84M | $352000.00 | $669000.00 | $2.13M | $1.16M | — |
| Effective tax rate | 0.0% | 3.9% | 36.3% | 50.1% | -0.5% | 0.4% | -1.7% | -0.5% | -0.0% | -0.1% | -0.4% | -0.6% | 0.0% |
| Net income | $-3.96M | $-10.79M | $-46.52M | $-27.12M | $-51.01M | $-127.50M | $-304.71M | $-344.87M | $-746.35M | $-652.17M | $-528.63M | $-197.88M | $22.39M |
| Net income growth (YoY) | — | -172.3% | -331.2% | +41.7% | -88.0% | -150.0% | -139.0% | -13.2% | -116.4% | +12.6% | +18.9% | +62.6% | +111.3% |
| Profit margin | — | — | — | — | — | — | — | -137.6% | -1121.3% | -864.7% | -133.3% | -25.3% | 2.2% |